Disease · MONDO_0005362
Comparisons in its trials32
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 32
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| 2.5 mg/5 mg Tadalafil vs 5 mg Tadalafil: serious adverse events | 15 of 210 | 17 of 421 | 631 | NCT02224846 | Trial comparisons |
| PDE5I + PLACEBO vs PDE5I + DPX: serious adverse events | 4 of 245 | 3 of 250 | 495 | NCT01063855 | Trial comparisons |
| MED2005 vs MED Placebo: deaths from any cause | 0 of 229 | 0 of 227 | 456 | NCT02495467 | Trial comparisons |
| MED2005 vs MED Placebo: serious adverse events | 0 of 229 | 0 of 227 | 456 | NCT02495467 | Trial comparisons |
| MED2005 vs MED Placebo: Number of Participants With Affirmative Response to Global Assessment Questionnaire (GAQ) Question 1 | 94 of 216 | 56 of 216 | 432 | NCT02495467 | Trial comparisons |
| MED2005 vs MED Placebo: Number of Participants With Affirmative Response to Global Assessment Questionnaire (GAQ) Question 2 | 85 of 216 | 54 of 216 | 432 | NCT02495467 | Trial comparisons |
| Vardenafil ODT (STAXYN, BAY 38-9456) vs Placebo: serious adverse events | 4 of 184 | 1 of 174 | 358 | NCT00631969 | Trial comparisons |
| Vardenafil ODT (STAXYN, BAY38-9456) vs Placebo: serious adverse events | 2 of 171 | 1 of 166 | 337 | NCT00655629 | Trial comparisons |
| Tadalafil vs Placebo: serious adverse events | 2 of 147 | 1 of 70 | 217 | NCT00836693 | Trial comparisons |
| MED3000 vs Tadalafil: deaths from any cause | 0 of 94 | 0 of 94 | 188 | NCT04984993 | Trial comparisons |
| MED3000 vs Tadalafil: serious adverse events | 0 of 94 | 1 of 94 | 188 | NCT04984993 | Trial comparisons |
| Vardenafil (Levitra, BAY38-9456) vs Placebo: serious adverse events | 0 of 75 | 0 of 72 | 147 | NCT00738400 | Trial comparisons |
| Vardenafil (Levitra, BAY38-9456) vs Placebo: Number of Participants Who Can Stay on the Initially Provided Dosage of Vardenafil (10 mg PRN (Pro re Nata)) | 28 of 75 | 13 of 70 | 145 | NCT00738400 | Trial comparisons |
| Dutasteride 0.5 mg vs Placebo: Number of Participants With Treatment-related AEs in the Double-blind Treatment Period | 11 of 58 | 5 of 59 | 117 | NCT02014584 | Trial comparisons |
| Dutasteride 0.5 mg vs Placebo: Number of Participants With Adverse Events (AE) Related to Sexual Function in the Double-blind Treatment Period | 9 of 58 | 5 of 59 | 117 | NCT02014584 | Trial comparisons |
| Dutasteride 0.5 mg vs Placebo: Incidence of Premature Discontinuations in the Double-blind Treatment Period | 6 of 58 | 2 of 59 | 117 | NCT02014584 | Trial comparisons |
| Dutasteride 0.5 mg vs Placebo: Number of Participants Who Discontinued Study Treatment Due to AEs Related to Sexual Function in the Double-blind Treatment Period | 0 of 58 | 0 of 59 | 117 | NCT02014584 | Trial comparisons |
| Dutasteride 0.5 mg (DB)/Dutasteride 0.5 mg (OL) vs Placebo (DB)/Dutasteride 0.5 mg (OL): Number of Participants With Treatment-related AEs in the Open-label Treatment Period | 2 of 48 | 4 of 49 | 97 | NCT02014584 | Trial comparisons |
| Dutasteride 0.5 mg (DB)/Dutasteride 0.5 mg (OL) vs Placebo (DB)/Dutasteride 0.5 mg (OL): Incidence of Premature Discontinuations in the Open-label Treatment Period | 1 of 48 | 5 of 49 | 97 | NCT02014584 | Trial comparisons |
Dutasteride 0.5 mg (DB)/Dutasteride 0.5 mg (OL) vs Placebo (DB)/Dutasteride 0.5 mg (OL): Number of Participants Who Discontinued Study Treatment Due to AEs Related to Sexual Function in the Open-label Treatment Period | 0 of 48 | 0 of 49 | 97 | NCT02014584 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005362/comparisons